The Bill & Melinda Gates Foundation’s TB Vaccine Accelerator Program is requesting applications for projects that will help meet one or both of the following two interrelated goals:
* To develop novel approaches to vaccination against Mycobacterium tuberculosis (Mtb), with a particular focus on approaches that aim to induce protection against infection with Mtb
* To develop models of natural Mtb transmission and methods for defining the relevant molecular and biological characteristics of naturally transmitted mycobacteria and of their interactions with vertebrate hosts
The prevention of tuberculosis (TB) through the development and deployment of an effective vaccine is a priority of the Bill & Melinda Gates Foundation. To strengthen the pipeline of vaccine candidates and enable a more rational and accelerated vaccine development process, the foundation, in collaboration with its Product Development Partner Aeras, recently launched the TB Vaccine Accelerator Program. With the assistance and support of the TB research and development community, a set of obstacles to TB vaccine development—and integrated goals that, collectively, could help to directly understand, overcome or work around these obstacles—have been selected. Through a research program focused on achieving this defined set of interdependent goals, the TB Vaccine Accelerator aims to address significant challenges in this field. This Request for Applications (RFA) focuses on two of these goals.
The complete RFA, along with instructions for submitting a Letter of Inquiry, can be found at:
This opportunity is closed
Interested applicants are asked to read the RFA document and are invited to submit a Letter of Inquiry before November 26, 2012.